Olfactory Ecto-Mesenchymal Stem Cells in Modeling and Treating Alzheimer’s Disease

Author:

Wang Hongmin1ORCID,Dwamena Abena1

Affiliation:

1. Department of Pharmacology and Neuroscience, Garrison Institute on Aging, Center of Excellence for Translational Neuroscience and Therapeutics, Texas Tech University Health Science Center, Lubbock, TX 79424, USA

Abstract

Alzheimer’s disease (AD) is a condition in the brain that is marked by a gradual and ongoing reduction in memory, thought, and the ability to perform simple tasks. AD has a poor prognosis but no cure yet. Therefore, the need for novel models to study its pathogenesis and therapeutic strategies is evident, as the brain poorly recovers after injury and neurodegenerative diseases and can neither replace dead neurons nor reinnervate target structures. Recently, mesenchymal stem cells (MSCs), particularly those from the human olfactory mucous membrane referred to as the olfactory ecto-MSCs (OE-MSCs), have emerged as a potential avenue to explore in modeling AD and developing therapeutics for the disease due to their lifelong regeneration potency and facile accessibility. This review provides a comprehensive summary of the current literature on isolating OE-MSCs and delves into whether they could be reliable models for studying AD pathogenesis. It also explores whether healthy individual-derived OE-MSCs could be therapeutic agents for the disease. Despite being a promising tool in modeling and developing therapies for AD, some significant issues remain, which are also discussed in the review.

Funder

NIH/NIA

Publisher

MDPI AG

Reference65 articles.

1. (2023). 2023 Alzheimer’s disease facts and figures. Alzheimers Dement, 19, 1598–1695.

2. Alzheimer’s disease drug development pipeline: 2024;Cummings;Alzheimer’s Dement. Transl. Res. Clin. Interv.,2024

3. (2024, July 05). Biogen to Realign Resources for Alzheimer’s Disease Franchise|Biogen. Available online: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise.

4. Regenerative Therapies for Central Nervous System Diseases: A Biomaterials Approach;Tam;Neuropsychopharmacology,2014

5. Neuroprotection in acute brain injury: An up-to-date review;Stocchetti;Crit. Care,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3